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O B J E C T I V E S We used human umbilical cord segments as an ex vivo model to investigate the
possible clinical diagnostic and therapeutic applications of microbubbles (MBs).
B A C KG ROUND Microbubbles are commonly used in clinical practice as ultrasound contrast
agents. Several studies have addressed the in vivo applications of MBs for speciﬁc targeting of vascular
dysfunction or sonoporation in animal models, but to date no human tissue model has been established.
METHOD S Primary venular endothelial cell monolayers were targeted with MBs conjugated to an
antibody against a highly expressed endothelial marker (tetraspanin CD9), and binding was assessed
under increasing ﬂow rates (0.5 to 5 dynes/cm2). Furthermore, CD9-coupled MB endothelial targeting
was measured under ﬂow conditions by contrast-enhanced ultrasound analysis in an ex vivo human
macrovascular model (umbilical cord vein), and the same tissue model was used for the detection of
inﬂamed vasculature with anti-intercellular adhesion molecule (ICAM)-1–coated MBs. Finally, plasmids
encoding ﬂuorescent proteins were sonoporated into umbilical cord vessels.
R E S U L T S Speciﬁc endothelial targeting in the in vitro and ex vivo models described previously was
achieved by the use of MBs covered with an anti-CD9. Furthermore, we managed to induce inﬂammation in
umbilical cord veins and detect it with real-time echography imaging using anti–ICAM-1–coupled MBs.
Moreover, expression and correct localization of green ﬂuorescent protein and green ﬂuorescent protein-
tagged ICAM-1 were assessed in this human ex vivo model without causing vascular damage.
CONC L U S I O N S In the absence of clinical trials to test the beneﬁts and possible applications of
ultrasound contrast agents for molecular imaging and therapy, we have developed a novel ex vivo
human model using umbilical cords that is valid for the detection of inﬂammation and for exogenous
expression of proteins by sonoporation. (J Am Coll Cardiol Img 2009;2:997–1005) © 2009 by the
American College of Cardiology Foundation
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998icrobubbles (MBs) are 2- to 8-m acous-
tically active particles consisting of a gas-
eous core surrounded by a biocompatible
shell typically composed of a mix of
ipids, albumin, or polymers. The resonant properties
f MB make them a powerful class of ultrasound
ontrast agents with both diagnostic and therapeutic
pplications. In this regard, MBs can be modified by
he conjugation to their shell of specific ligands, such
s peptides or monoclonal antibodies, to create site-
argeted MBs able to detect molecular changes in
See page 1006
ndothelium (e.g., inflammation, thrombosis, an-
iogenesis) (1). Insonation of MBs can produce
ransitory micropores at cell membranes (2), offer-
ng the possibility of delivering bioactive substances
r genetic material into surrounding cells, a proce-
ure termed sonoporation (3).
To date there have been several reports of
ultrasound (US) imaging of MBs and sono-
poration in human vascular monolayers cul-
tured in vitro (4,5). Using a human ex vivo
model based on umbilical cord segments, we
evaluated real-time US molecular imaging
of MBs targeted either to a general endo-
thelial surface receptor (CD9) or a marker of
inflamed endothelium (intercellular adhe-
sion molecule [ICAM]-1) and assessed the
feasibility of sonoporation for the delivery of
functional plasmids to the endothelium of a
human vessel.
E T H O D S
icrobubble preparation. Biotinylated lipid-
ncapsulated perfluorocarbon MBs were purchased
Targeson LLC, Charlottesville, Virginia). Micro-
ubbles were prepared following manufacturer’s in-
tructions at a final concentration of 4 to 5 106 MBs
er milliliter in saline solution, as determined with a
emocytometer XT-1800i (SYSMEX, Mundelein,
llinois). Alternatively, a vial of SonoVue (Bracco
nternational B.V., Amsterdam, the Netherlands) was
esuspended following the manufacturer’s instructions
8 l of sulphur hexafluoride per milliliter).
ltrasound image acquisition from umbilical cord seg-
ents. The veins of umbilical cord segments were
annulated and washed with a heparinated solution
20 UI/ml). Paired segments from the same cord
ere treated as follows: one was filled with 199
ein
nedium containing growth factors and the other dith medium with 100 ng/ml tumor necrosis factor
TNF)- to induce inflammatory conditions. Both
egments were incubated 20 h at 37°C and were
hen immersed in a saline bath at 37°C for MB
erfusion using an automated infusion syringe
ump (VueJect [BR-INF 100, Bracco Research SA,
eneva, Switzerland]) and image acquisition. Seg-
ents were scanned with a Vivid i digital cardio-
ascular ultra-portable ultrasound system (GE
ealthcare, Milwaukee, Wisconsin) with an i12LR
igh-frequency linear transducer (up to 13 MHz,
sing 4.5 to 9.9 MHz with second harmonic).
olutions of MB (2 to 5 million MB per milliliter in
total volume of 10 ml) were perfused using a
ump at 1.6 ml/min. Video sequences were stored
nd subsequently analyzed with EchoPac 6.3 soft-
are (GE Healthcare).
onoporation of endothelium in intact human umbilical
ord blood vessels. For sonoporation, the Vivid i
igital ultrasound system with a different transducer
S3 multifrequency) (GE Healthcare) was used. A
olution of SonoVue mixed with 20 g/ml plasmid
eoxyribonucleic acid (DNA) was introduced into
he lumen of umbilical arteries, and the vessels were
ied off at both ends. Insonation was performed at
armonic imaging (1.7 to 3.4 MHz) at a high frame
ate (112 Hz) and at a high mechanical index (1.3)
or 5 min. After insonation, artery segments were
aintained for 20 h in growth factor supplemented
edium 199, fixed in 4% paraformaldehyde, and
rocessed for tissue microscopy analysis. In the case
f umbilical vein experiments, 10 ml of the same
ixture of MB and complementary DNA were
erfused with a VueJect pump (Bracco Imaging,
ilan, Italy) at a rate of 1.6 ml/min across human
ndothelial veins with simultaneous insonation that
sed the same frequency and mechanical index but
frame rate between 25 and 35 Hz. Then, endo-
helial cells were isolated from the vein (6) imme-
iately after insonation and cultured for 20 h before
eing fixed in 4% paraformaldehyde and prepared
or cellular microscopy analysis (Online Appendix).
nstitutional Review Board approval for the studies
as obtained from the National Center of Cardio-
ascular Research and Hospital Universitario de la
rincesa (IRB00005840).
E S U L T S
icrobubble-mediated speciﬁc targeting under con-
rolled physiological shear ﬂow. To evaluate specific
argeting of human vascular tissues with US contrast
gents (MB), we first analyzed the ability of antibody-B B R E V I A T I O N S
N D A C R O N YM S
GFP enhanced green
uorescent protein
UVEC human umbilical v
ndothelial cell
CAM intercellular adhesio
olecule
Bmicrobubble
NF tumor necrosis factorirected MBs to bind endothelial surfaces under flow
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999onditions. Monolayers of primary human umbilical
ein endothelial cells (HUVECs) were either left
nder resting conditions or were activated with the
roinflammatory cytokine TNF- and then mounted
n an inverted parallel flow chamber for MB attach-
ent evaluation by optical microscopy.
To test specific endothelial targeting, biotinylated
argestarB MBs were coupled to an antibody against
D9 (a cell-surface protein highly expressed in HU-
ECs) (Fig. 1A) (7). For controls, we used naked
nonantibody-coupled) biotinylated MB and biotinyl-
ted MB coupled to an isotype-matched antibody
aised against the adhesion molecule ICAM-3 (whose
xpression is hardly detectable in HUVECs) (Fig.
A). The MBs were drawn across the HUVECs at
ncreasing flow rates, and the numbers of attached
B at each flow rate were counted and compared
etween different treatments (Figs. 1B and 1C). Non-
pecific binding was assessed by the binding of MBs to
lates coated with the substratum used for HUVEC
ultures (fibronectin) and was very low in all cases.
We found that MBs coated with anti-CD9 (anti-
D9-MB) bound strongly to resting and activated HU-
EC monolayers, showing up to 9-fold greater binding
han controls. The exponential phase of binding lasted
p to 2 dynes/cm2. The MB binding was impaired by
he increasing shear stress at high flow rates; however,
here was no significant detachment during the experi-
ent and the subsequent washout, indicating strong
ttachment. Isotype-control MBs and naked MBs
howed some residual nonspecific binding that decreases
ith the increase of flow rate (Fig. 1B).
eal-time echography imaging of MB-mediated vascu-
ar targeting in ex vivo human umbilical cord veins.
aving validated endothelial targeting of MB in the
n vitro flow chamber, we next evaluated vascular MB
argeting in an ex vivo model of human macrovascular
issue, the umbilical cord vein. Umbilical veins in cord
egments were perfused with anti–CD9-MB, and
mages were collected throughout the experiment
ntil after the last washout. We found that MB
emained acoustically active after conjugation with
ntibody, and individual MBs attached to the vein
all were even detected with submillimetric resolu-
ion. During the washout period, the umbilical vein
as fully coated with MB, delineating the vein wall.
o rule out nonspecific adhesion, parallel control
xperiments were conducted with the ICAM-3–
argeted and naked MBs; no significant attachment of
B was detected in either case (Fig. 2A). Quantita-
ive analysis of contrast-enhanced US video intensity
learly demonstrated the specificity of anti–CD9-MB
inding compared with the residual adsorptive attach- cent of control antibody-coupled or naked MB (Figs.
B and 2C).
etection of inﬂamed endothelium by MB-mediated
argeting. CD9 is constitutively expressed in endo-
helial cells, and its membrane expression is not
ignificantly altered by proinflammatory stimulation
7). Accordingly, treatment of umbilical cord veins
ith proinflammatory stimuli (TNF-) produced no
hange in the specific targeting of anti–CD9-MB
data not shown). To specifically target inflamed vascu-
ar beds, we conjugated MBs to an antibody against the
dhesion molecule ICAM-1, which is up-regulated dur-
ng inflammation. The effectiveness of the inflammatory
ctivation was confirmed by isolating HUVECs from
NF-–treated umbilical veins and determining the
latelet/endothelial cell adhesion molecule (PECAM)-
/(CD31)–ICAM-1/(CD54) double-positive popula-
ion by fluorescence-activated cell sorting; cell-surface
xpression of ICAM-1 after TNF- treatment was
ncreased 2-fold with respect to resting conditions (Fig.
A). Ultrasound imaging of ICAM-1–targeted MB
arely detected basal ICAM-1 expression in resting
mbilical cords, whereas a 10-fold increase in MB
inding was observed in inflamed tissue, demonstrat-
ng the ability of the technique to identify sites of local
nflammation in the macrovasculature (Fig. 3B).
nalysis of tissue integrity after US insonation at high
echanical index. To achieve efficient in situ trans-
ection of DNA plasmids directly into intact endothe-
ium, we attempted to induce transitory micropores in
he luminal endothelial membrane of umbilical vessels
y destroying MBs with sustained high-power in-
onation (mechanical index: 1.2 to 1.4). Before pro-
eeding with transfection, we first assessed the effect of
he insonation on tissue integrity by immunohisto-
hemical analysis. Hematoxylin and eosin staining
evealed no apparent tissue deterioration with US
nsonation (Fig. 4A). Immunostaining of CD31/
ECAM-1 and 4’,6-diamidino-2-phenylindole
DAPI) staining for nuclei confirmed that the integ-
ity of the monolayer seemed to be preserved (Fig.
B). To test for possible changes in paracellular
ermeability, umbilical cord segments were incubated
fter insonation with fluorescein isothiocyanate
FITC)/dextran (77 kDa). Microscopy analysis of
ryostat sections revealed an increase in paracellular
ermeability in US-treated cord samples compared
ith noninsonated cord samples. This increase was
ot significantly greater than that induced by our stan-
ard inflammatory treatment with TNF- (Fig. 4C).
onoporation of plasmid DNA in human umbilical cord
eins and arteries. Having established that US appli-
ation at high mechanical index does not produce
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Figure 1. Study of Microbubble Speciﬁc Targeting Using a Parallel Plate Flow Chamber
(A) Flow cytometry analysis of CD9 (green) and intercellular adhesion molecule (ICAM)-3 (orange) expression in resting and tumor necro-
sis factor-–activated human umbilical vein endothelial cells (HUVECs). Inducible ICAM-1 expression (blue) was used as positive control
of tumor necrosis factor-–induced HUVEC activation, and X-63 (red) was used as negative control. (B) Time course of attachment of
TargestarB microbubbles under ﬂow conditions. Noncoupled biotinylated microbubbles (naked TargestarB, green), microbubbles coupled
to anti-CD9 (blue), or to an isotype-matched ICAM-3 control antibody (red) were perfused at increasing ﬂow rates over ﬁbronectin, rest-
ing or activated HUVEC monolayers. Microbubble attachment to each substrate was quantiﬁed over time and represented in 2 different
types of histograms (cumulative or noncumulative binding events). (C) Representative images of control versus anti–CD9-coupled micro-
bubbles attached to resting HUVEC monolayers during the post-treatment washout period. Boxed areas are shown at high magniﬁcation
in the lower panels. Microbubbles attached to the endothelial monolayers are marked with a red outline; those out of the focal plane
2were considered as not interacting with the endothelium. Screen area  0.06 mm . TNF  tumor necrosis factor.
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Figure 2. Echographic Analysis of Microbubble-Speciﬁc Targeting in Human Umbilical Cords
(A) Representative echographic images of the long and short axes of human umbilical cords perfused with naked, control antibody-, or
anti–CD9-coupled TargestarB microbubbles. Images are of umbilical cords maintained under resting or tumor necrosis factor- inﬂamma-
tory conditions. Dashed yellow lines delineate the luminal area to distinguish the MB attached to endothelium from free-ﬂowing ones.
(B) Representative isosurface plots of negative (left) and positive (right) targeting images from long (top) and short axes (bottom). (C) In
the box and whisker plots, the box extends from the 25th percentile to the 75th percentile, with a line at the median (the 50th percen-
tile). The whiskers extend above and below the box to show the highest and lowest values of contrast-enhanced ultrasound video inten-
sity measured in echographic images from every treatment (n ranging from 10 to 18). Statistical analysis was performed with a Kruskal-
Wallis test (p  0.0001) with Dunn’s multiple comparison post-test (p values for all pairs of columns shown in the ﬁgure).
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1002ross denudation of the endothelium, we evaluated
he method for in situ sonoporation of complementary
NA plasmids. We first confirmed US-mediated
B destruction by optical microscopy or ultrasound
maging (data not shown). For sonoporation, a mix-
ure of SonoVue MB and plasmid DNA encoding
nhanced green fluorescent protein (EGFP) was in-
luded in the lumen of umbilical arteries and incu-
ated under static conditions with simultaneous in-
onation. Confocal fluorescence analysis of arterial
issue revealed in situ EGFP expression in the endo-
helium 24 h after sonoporation (Fig. 5A). Moreover,
Figure 3. Echographic Detection of Inﬂammation by Speciﬁc Mi
(A) Umbilical cords were treated with either resting or inﬂammatory co
nase P treatment, and expression of ICAM-1 in PECAM-1 (endothelial
images from long and short axes of human umbilical cords treated wi
coupled TargestarB microbubbles. Dashed yellow lines delineate the lu
from free-ﬂowing ones. The scatter plot shows contrast-enhanced ultra
Statistical analysis was performed using an unpaired t test with Welch’mixture of SonoVue MB and ICAM-1–EGFP ilasmid was perfused across umbilical veins with
imultaneous insonation. Then, cells were isolated and
ultured in vitro 24 h before microscopy analysis. In
his way, we further confirm that delivered genes were
orrectly expressed because ICAM-1–EGFP was ap-
ropriately localized at the HUVEC plasma mem-
rane, concentrated in microclusters and staining mar-
inal microvilli (Fig. 5B).
I S C U S S I O N
he combination of US application with the admin-
ubble Targeting
tions for 16 to 20 h, then endothelial cells were isolated by collage-
ls was analyzed by ﬂow cytometry. (B) Representative echographic
sting or inﬂammatory conditions and perfused with anti–ICAM-1–
al area to distinguish the microbubbles attached to endothelium
nd video intensity values measured in images from both treatments.
rrection (p value shown in the ﬁgure).crob
ndi
) cel
th re
min
soustration of targeted MB is an attractive and well-
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1003Figure 4. Study of Endothelial Viability After High Mechanical Index Ultrasound Treatment
(A) Hematoxylin and eosin staining of tissue slices from umbilical cords exposed to no treatment or to high mechanical index ultra-
sounds. Images on the left are full cross sections of the umbilical cords. The white boxed areas on them are shown at greater magniﬁca-
tion to the right. Histology experiments were performed on 3 to 4 different cord segments for each condition, and 2 to 3 sections were
analyzed from each segment (B) Immunostaining of tissue slices from umbilical cords shown in (A). Endothelial cells were stained with
an speciﬁc marker (CD31) in red and nuclei were stained with DAPI. Bar  40 m. (C) Effect of high mechanical index ultrasound on ves-
sel wall integrity. Umbilical cords were subjected as indicated to resting or inﬂammatory conditions for 20 h or, alternatively, ﬁlled with a
SonoVue MB solution and treated with high mechanical index ultrasounds for 5 min (US  MB) or left untreated (no treatment). Cords
were perfused with ﬂuorescein isothiocyanate (FITC)/dextran, and samples processed for ﬂuorescence microscopy analysis. The histo-
grams show ﬂuorescence intensity along the line depicted on the corresponding image. All images were acquired by confocal micros-
copy using the same photomultiplier parameters. Bar  25 m.
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1004alanced technique for both in vitro and in vivo use
ecause of its noninvasive nature, its wide availability
nd relatively low cost, and its high spatiotemporal
esolution, which provides sensitivity to low concen-
rations of targeted MB with a signal-to-noise ratio
uitable for clinical use. Endothelial targeting offers
reat possibilities for detecting dysfunctional endothe-
ium in atherosclerosis, vulnerable plaques, and pro-
esses associated with myocardial dysfunction such as
schemia/reperfusion or transplant rejection (8,9).
ltrasound contrast agents coupled to antibodies
irected against specific vascular markers have been
uccessfully applied in animal models during the
ast decade (10,11) to monitor endothelial damage
r dysfunction (12), inflammation (13), angiogen-
sis (14), and thrombosis (15). However, no study
n human tissue has been reported previously.
To evaluate endothelial targeting with MB in intact
uman tissue, we performed experiments on the
uman umbilical cord vein and artery. The human
mbilical vein is a good example of macrovasculature,
aving a similar caliber (5 to 8 mm) to other medium-
ized vessels such as the renal artery or saphenous vein.
he efficiency of MB targeting for a given concentra-
ion is probably lower in macrovessels than in smaller
ascular beds because the likelihood of interaction
ith the vessel wall for each individual MB is much
educed. For this reason, we selected CD9 tetra-
n of Umbilical Cord Artery and Vein
e expression of enhanced green ﬂuorescent protein after sonopora-
d artery at high mechanical index. 4’,6-diamidino-2-phenylindole
i (blue) was used to distinguish endothelial cells (EC) from muscle
rance of their nuclei reﬂects the orthogonal orientation of these cell
responds to elastin autoﬂuorescence in the vascular smooth muscle
ange signal corresponds to pseudocolored enhanced green ﬂuores-
er image analysis with Spectral Dye Separation tool by Leica Confo-
showing the localization of intercellular adhesion molecule-1-
cent protein at the plasma membrane of an endothelial cell grown
anical index sonoporation of a SonoVue-loaded umbilical cord vein.panin, a molecule that is a highly expressed marker in oacrovasculature and microvasculature (16), as well as
n lymphatics (17), and we succeeded in detecting the
ntire luminal surface of the umbilical vein. CD9 plays
n essential role in cell adhesion, proliferation and
igration, platelet aggregation, and tumor metastasis
18). Our group has also described a regulatory role for
D9 in the adhesion mediated by a variety of endo-
helial receptors (including vascular cell adhesion mol-
cule [VCAM]-1 and ICAM-1) during leukocyte
xtravasation, a key event in the inflammatory re-
ponse (7,19). This role suggests that localized release
f blocking antibodies against CD9 might have po-
ential as a general and more effective anti-
nflammatory therapy than the single inhibition of one
f these adhesion molecules. However, CD9 is not
nly expressed by endothelial cells but also by a
umber of blood cell subsets (including platelets,
eutrophils, and monocytes) (7,20). Therefore, the
dministration of CD9 blockers would require a lo-
alized release in inflammatory foci, which could be
ccomplished by their combination with antibodies
gainst any inflammatory marker in the same MB.
Inflammation is a crucial component of many
ardiovascular disorders from the earliest stages, and
he potential of MB to identify sites of inflammation
s therefore of great interest. In small animal models,
nflammation can be visualized and quantified by
ntroducing MB targeted to several well-established
iomarkers such as P-selectin (21) or VCAM-1 (22).
ere, we have developed an ex vivo model of inflam-
ation in human macrovasculature by using ICAM-1
s an inflammatory marker. We found that ICAM-1
s expressed at basal levels in resting endothelium, but
his basal expression seems to be below the detection
hreshold of our imaging technique. Therefore, the
nti–ICAM-1–tagged MB specifically highlighted
he endothelium of vessels exposed to proinflamma-
ory stimuli, validating this approach as a means of
etecting inflammatory foci in large vessels.
The use of MB in combination with US has been
hown to promote gene delivery in a variety of
xperimental animal models (reviewed in Miller et al.
23]). Our ex vivo experiments in human umbilical
ord vessels show that sonoporation is practicable in
he human vasculature. However, the transfection
fficiency was limited by the fact that the cells in the ex
ivo model remain in a quiescent-like state, with low
etabolic activity, which precludes a high protein
ield from the transfected plasmid. Moreover, our
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